BOSTON & BASEL, Switzerland–(BUSINESS WIRE)–#RNA–Genevant Sciences, a leading biopharmaceutical company focused on the
discovery and development of RNA therapeutics utilizing multiple
modalities, today announced that Bo Rode Hansen, MBA, PhD, President and
Chief Executive Officer, is scheduled to present at the Jefferies 2019
Healthcare Conference in New York City on Friday, June 7, 2019 at 8:00
am EDT.
About Genevant Sciences
Genevant leverages best-in-class RNA therapeutic delivery capabilities
to develop a diverse pipeline of innovative product candidates designed
to improve lives. While others are focused singularly on a particular
RNA modality, Genevant’s lipid nanoparticle (LNP) technology, which
enabled the first RNAi product approval, and ligand conjugate technology
provide the potential to exploit multiple modalities, including mRNA,
RNAi and gene editing, and to select the optimal one on a
target-by-target basis. Genevant’s pipeline programs include both rare
diseases with well established, monogenic causes and unique therapeutic
approaches to more complex, large market diseases. Genevant is committed
to transforming the future of human health.
To learn more about us, please visit: www.genevant.com.
Contacts
Media:
Karen Sharma
MacDougall
[email protected]
Investor:
[email protected]
